louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02738424: Reproductibility of Lumbar Spine ADC Based on Different Post-processing Softwares
Official title: Reproductibility of Lumbar Spine ADC Based on Different Post-processing Softwares
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Low Back Pain
Keywords: Low Back Pain
MRI
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2016-04-14
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The population studied is composed of 100 patients that will performed an MRI in the CHU de Saint-Etienne. They have lumbar pain, and the MRI is indicated off-study.

Brief summary: Lumbar spine bone marrow is well explored in Magnetic Resonance Imaging (MRI) but some bone marrow diseases are hard to analyze with this method. Furthermore, there is heterogeneity in normal bone marrow, called apparent diffusion coefficient (ADC). Histological and technical factors appear to be the cause, but the possible influence of the employed post-processing software has never yet been evaluated. The purpose of this study is to determine if there is variability in lumbar bone ADC related to the post-processing software.

Detailed description: Lumbar spine bone marrow is well explored in MRI. Some bone marrow diseases are hard to analyze in conventional MRI, and diffusion-weighted imaging (DWI) could be an additional diagnostic feature. However, according to the literature, there is heterogeneity in normal bone marrow of the quantitative parameter that it provides, called apparent diffusion coefficient (ADC). Histological and technical factors appear to be the cause, but the possible influence of the employed post-processing software has never yet been evaluated. The purpose of this study is to determine if there is variability in lumbar bone ADC related to the post-processing software.

Eligibility criteria: Inclusion Criteria:

* Consecutive patients undergoing lumbar spine MRI at University Hospital of Saint-Etienne

Exclusion Criteria:

* \<18 years old

Primary outcomes:
measure: ADC Score according to the post-processing software used
timeFrame: 1 day
Secondary outcomes:
measure: ADC Score according to the intensity of MRI
timeFrame: 1 day
Other outcomes:
Locations:
city: St Etienne
country: France
facility: Chu Saint Etienne
state: Saint Priest En Jarez
Study officials:
affiliation: CHU SAINT-ETIENNE
name: Claire BOUTET, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00642824: A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Official title: Local Substudy Associated to the International Study MO19390 to Determine the BRCA1 Gene mRNA Expression as a Predictive Marker of Response to Chemotherapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2008-03-25
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This single arm genetic substudy of MO19390 will test the hypothesis that there is a positive relationship between mRNA BRCAI levels and the response to different chemotherapy combinations plus Avastin. A subset of patients participating in MO19390, and receiving Avastin 15mg/kg iv on day 1 and subsequently once every 3 weeks, will undergo BRCAI mRNA expression determination. Depending on the BRCAI mRNA level (low, medium or high) they will receive a different chemotherapy regimen in combination with Avastin: a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel. Avastin treatment will continue after completion of chemotherapy cycles until disease progression, and the target sample size is 100-500 individuals.


Eligibility criteria: Inclusion Criteria:

* participating in, and meeting all inclusion/exclusion criteria of, MO19390.

Exclusion Criteria:

* not meeting the inclusion/exclusion criteria of MO19390.

Primary outcomes:
measure: Progression-free survival
timeFrame: Event driven
Secondary outcomes:
measure: Overall survival; response rates
timeFrame: Event driven
measure: Adverse events
timeFrame: Throughout study
Other outcomes:
Locations:
city: Alcorcon
country: Spain
city: Alcoy
country: Spain
city: Alicante
country: Spain
city: Badalona
country: Spain
city: Barakaldo
country: Spain
city: Burgos
country: Spain
city: Elche
country: Spain
city: Girona
country: Spain
city: Huesca
country: Spain
city: La Laguna
country: Spain
city: Las Palmas de Gran Canaria
country: Spain
city: Lugo
country: Spain
city: Madrid
country: Spain
city: Madrid
country: Spain
city: Madrid
country: Spain
city: Murcia
country: Spain
city: Palma de Mallorca
country: Spain
city: Pamplona
country: Spain
city: Salamanca
country: Spain
city: Valencia
country: Spain
city: Valencia
country: Spain
city: Zaragoza
country: Spain
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT04905524: Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)
Official title: Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression, Anxiety
IBS - Irritable Bowel Syndrome
Keywords: Depression
Anxiety
Irritable bowel syndrome
Viome precision nutrition program
VNPN
IBS
PHQ9
GAD7
ROME-IV
Viome
Diet
Nutrition
Supplements
Lead sponsor: Viome
Sponsor class: INDUSTRY
First posted: 2021-05-27
Enrollment: 10000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This is a single group cohort study; the first cohort consists of participants with self reported Irritable Bowel Syndrome (IBS), the second cohort consists of participants with self reported depression and the last cohort consists of participants with self reported anxiety.

All cohorts receive diet and supplement recommendations from Viome based on participants' sample results.
Primary purpose: SUPPORTIVE_CARE

Brief summary: Viome costumers are consented and recruited for this study and complete the questionnaires upon enrollment. Any participant who previously self reported depression, anxiety, or Irritable Bowel Syndrome (IBS) qualify for this study.

All participants receive Viome's diet, supplement and recommendations.

Detailed description: Participants receive Viome Precision Nutrition Program (VPNP) after completing the health assessment and questionnaire. VPNP consists of diet, supplement and recommendations based on results from their sample results and their self reported questionnaire.

After approximately 5 months, participants were given the same health assessment questionnaire.

The results and data collected before and after the VPNP are analyzed to find correlations and differences between the measurements taken at the beginning of the trial and again approximately 5 months after.

Eligibility criteria: Inclusion Criteria:

* PHQ-9 score 5 or above
* GAD-7 score 5 or above
* IBS ROME-IV score 125 or above
* Females and males aged 18 years or older
* Signed and dated informed consent prior to any trial-specific procedures are performed
* Able to speak and read English
* Willing and able to follow the trial instructions
* Viome existing costumer

Exclusion Criteria:

* Unable/unwilling to complete the provided questionnaires

Primary outcomes:
measure: Disease activity changes for IBS
timeFrame: ~5 months
measure: Disease activity changes depression
timeFrame: ~5 months
measure: Disease activity changes anxiety
timeFrame: ~5 months
Secondary outcomes:
Other outcomes:
Locations:
city: Bothell
country: United States
facility: Viome Research Institute
state: Washington
Study officials:
affiliation: Viome
name: Momo Vuyisich, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06973824: A Twenty-years' Experience in Pituitary Disease.
Official title: A Twenty-years' Experience in Pituitary Disease: Identification of Prognostic Factors in Pituitary Tumors
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pituitary Adenoma
Pituitary Cancer
Pituitary Disease
Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sponsor class: OTHER
First posted: 2025-05-15
Enrollment: 1600
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients older then 18 years with diagnosis of pituitary tumors (pituitary adenoma, pituitary neuroendocrine tumors, meningiomas, craniopharingiomas, germinoma, metastasis)

Brief summary: Pituitary tumors represent a heterogeneous group of neoplasms by histotype. The pituitary adenomas are the most frequent heteroformation, among those affecting the pituitary gland, followed by meningiomas, craniopharyngiomas, germosomes and tumours secondary, such as metastases and lymphomas. Since these conditions are considered rare, the data epidemiology and prognosis to predict the natural history of these diseases can not be considered conclusive. Pituitary adenomas are a useful model for epidemiology in the study of pathology pituitary. Over the past 20 years, several attempts have been made to identify unique prognostic factors, which predict the outcome of these pathologies, but without To arrive at a definitive classification. The purpose of this study aims to collect clinical, biochemical, morphological and pathological data on the retrospective and prospective cohort of over 1600 patients undergoing neurosurgical removal of pituitary tumors in the last 20 years, to develop a prognostic classification.


Eligibility criteria: Inclusion Criteria:

* Patients underwent surgery for pituitary tumors;
* pathology diagnosis of pituitary tumors;
* patients older then 18 years at diagnosis of pituitary tumors;
* 2 years follow-up;

Exclusion Criteria:

* age lower then 18 years
* follow-up shorter than 2 years

Primary outcomes:
measure: Tumor recurrence
timeFrame: From enrollement to last observation at 24 months of follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Fondazione Policlinico Gemelli IRCCS
state: IT
Study officials:
affiliation: Fondazione Policlinico Universitario A. Gemelli, IRCCS
name: Francesco Doglietto, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01248234: Does Administration of Etomidate and Propofol of the Anesthetic Induction of Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngoscopy When Compared to Propofol or Etomidate Alone?
Official title: Does Administration of Etomidate and Propofol if the Anesthetic Induction of the Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngosacopy, When Compared to Propofol or Etomidate Alone?
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Hypertension
Keywords: elderly
hypertensive
anesthesia
Lead sponsor: University of Mississippi Medical Center
Sponsor class: OTHER
First posted: 2010-11-25
Enrollment: 0
Sex: ALL
Minimum age (years): 65
Maximum age (years): 90
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: This study will attempt to show that a combination of drugs, Etomidate and Propofol, provide a more stable blood pressure when used to put elderly hypertensive patients to sleep than either drug used alone.

Detailed description: Same as above.

Eligibility criteria: Inclusion Criteria:

* Patients at least 65 years old, with a history of hypertension.

Exclusion Criteria:

* Patients less than 65 years old or without a history of hypertension.

Primary outcomes:
measure: Blood pressure stability during anesthetic induction
timeFrame: 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Jackson
country: United States
facility: University of Mississippi Medical Center
state: Mississippi
Study officials:
affiliation: University of Mississippi Medical Center
name: Cynthia A Vaughn, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00560534: Whole Body Magnetic Resonance Angiography With Subsystolic Venous Compression
Official title: Whole Body Magnetic Resonance Angiography in Patients With Symptomatic Peripheral Ischemia. Experience With Venous Compression.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atherosclerosis
Intermittent Claudication
Keywords: Magnetic resonance
whole body
angiography
venous compression
MRI
Lead sponsor: Copenhagen University Hospital at Herlev
Sponsor class: OTHER
First posted: 2007-11-19
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with peripheral arterial disease

Brief summary: To investigate the diagnostic performance of whole body magnetic resonance angiography (WB-MRA) using subsystolic venous compression of the thigh.

Detailed description: WB-MRA is an examination that can evaluate the arteries from head to feet. Timing of the injected bolus of contrast medium can be difficult, especially in the legs. As the result of the WB-MRA depends on the contrast medium only being in the arteries at the time of examination, the use of venous compression is a possible way of overcoming the problem of early venous filling, that can hamper the diagnostic value of the examination. Venous compression is performed with a blod pressure cuff around the thighs. It is inflated to subsystolic pressure (45 mm Hg). This elevated pressure leads to filling of the lower leg arteries and late venous filling.

Eligibility criteria: Inclusion Criteria:

* Symptomatic lower extremity ischemia (claudication, ischemic wounds)
* Referred to digital subtraction angiography (DSA)

Exclusion Criteria:

* Renal insufficiency (GFR \< 30 ml/min)
* Contra-indications for MRI-examination (claustrophobia, metal-implants, pacemaker)
* Dementia
* Pregnancy/lactation
* Allergy to gadolinium based MRI contrast agents
* Acute disease

Primary outcomes:
measure: Vascular diagnostic quality on the WB-MRA. Degree of arterial stenosis on the WB-MRA
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Herlev Copenhagen
country: Denmark
facility: Department of Radiology, Herlev University Hospital
state: Herlev
Study officials:
affiliation: University Hospital at Herlev Copenhagen Denmark
name: Henrik S Thomsen, Prof. MD.
role: STUDY_CHAIR
References:
Clinical trial NCT05539534: Effect of Suicide Prevention Training for Professionals
Official title: Effect of Suicide Prevention Training for Professionals on Knowledge and Attitudes Regarding Suicide Prevention
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Knowledge, Attitudes, Practice
Lead sponsor: University Ghent
Sponsor class: OTHER
First posted: 2022-09-14
Enrollment: 10000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Annually a substantial number of courses and trainings are organised in Flanders with regard to suicide prevention.These trainings are mainly aimed at intermediaries, such as caregivers, teachers, police, etc. From previous research it appears that such trainings are one of the most effective strategies for increasing knowledge, attitudes, skills and self-confidence with regard to dealing with persons who are suicidal and with crisis situations. However, such research has not yet been conducted in Flanders, which means that the effect of the training on the knowledge and attitudes of the intermediaries could not yet be determined. Therefore, this study aims to determine the effect of the trainings in Flanders. These trainings are organised by the Centre for the Prevention of Suicide (CPZ) and by the suicide prevention workers of the Centers for Mental Health Care.

All participants who register for one of these trainings will be invited by e-mail at three moments to complete an online questionnaire:

* Pre-test: one week before the training,
* Post-test: after the training,
* Follow-up: three months after training.


Eligibility criteria: Inclusion Criteria:

* Participating in a suicide prevention training organised by 'Centrum ter Preventie van Zelfdoding' or 'Suïcidepreventiewerking Centra Geestelijke Gezondheidszorg'

Exclusion Criteria:

* Not participating in a suicide prevention training organised by 'Centrum ter Preventie van Zelfdoding' or 'Suïcidepreventiewerking Centra Geestelijke Gezondheidszorg'

Primary outcomes:
measure: Degree of knowledge and attitudes on suicide and suicide prevention
timeFrame: Change in knowledge and attitudes at baseline (i.e., from one week before the start of the training) compared to post-test (immediately after the training, i.e. up to 3 days) and follow-up (3 months after post-test)
Secondary outcomes:
measure: Rate of responses to suicide
timeFrame: Change in Response to suicide at baseline (i.e., from one week before the start of the training) compared to post-test (immediately after the training, i.e. up to 3 days) and follow-up (3 months after post-test)
Other outcomes:
measure: Socio-demographic characteristics
timeFrame: Baseline (i.e., from one week before the start of the training)
measure: Evaluation of the training
timeFrame: Post-test (immediately after the training, i.e. up to 3 days)
Locations:
city: Ghent
country: Belgium
facility: Ghent University Hospital
Study officials:
affiliation: University Hospital, Ghent
name: Gwendolyn Portzky, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00768534: Study Evaluating Microbiological Analysis of Spontaneous Draining Acute Otitis Media
Official title: Microbiological Analysis Of Spontaneous Draining Acute Otitis Media Including Serotype Distribution Of Pneumococcal Isolates
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Otitis Media
Keywords: Acute Otitis Media
Serotype distribution
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-10-08
Enrollment: 2138
Sex: ALL
Minimum age (years): 2
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: community sample

Brief summary: Describe the patient population and bacterial microbiology of pediatric patients presenting with spontaneous draining acute otitis media


Eligibility criteria: Inclusion Criteria:

Main inclusion criteria:

* Children \>= 2 months and =\< 5 years
* Spontaneous draining AOM =\< 2 days Main

Exclusion Criteria:

exclusion criteria:

* Previous operation of the ear
* Chronic otitis media or tube placement with drainage \>= 3 days
* Chronic disease/immune deficiency

Primary outcomes:
measure: serotype distribution
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Tegernsee
country: Germany
facility: Dr. Andreas Busse
state: Bavarian
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00054834: Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
Official title: A Phase I Clinical Trial of Radiolabeled Immunotherapy With Humanized LL2 in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Non-Hodgkins Lymphoma
Lead sponsor: Gilead Sciences
Sponsor class: INDUSTRY
First posted: 2003-02-13
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.


Eligibility criteria: Disease Characteristics:

* Patients with a documented histologic or cytologic diagnosis of B-cell NHL.
* Patients who have failed at least one regimen of chemotherapy and are not eligible for any alternate therapies of higher therapeutic priority.
* Patients with at least one measurable tumor site \> 1.5 cm in at least one dimension.

Prior/Concurrent Therapy:

* Chemotherapy: Patients must have failed standard therapy or are not eligible for any alternate therapies of higher therapeutic priority.
* Biologic Therapy: Patients who have received human or humanized monoclonal antibodies will be eligible provided pre-study evaluations demonstrate no significant reactivity with hLL2 IgG (i.e., HAHA).
* Radiotherapy: No prior radiation therapy to \>25% of the bone marrow. No prior radiation to maximal tolerable levels for any critical organ (e.g., 2,000 cGy for the lungs and kidneys). Patients who have had whole pelvic irradiation are not eligible.

Patient Characteristics/Inclusion Criteria:

* Age Range: Male or Female at least 18 years of age
* Performance Status: Patients with a Karnofsky performance status \> 60% (or equivalent, ECOG 0-2) and expected survival of at least 12 weeks.
* Hematopoietic: Hemoglobin \> 10 g/dL; ANC \> 1.5x10\^9/L; Platelets \> 100x10\^9/L;
* Hepatic: Serum bilirubin \< 2.0 mg/dL; AST and ALT \< 2 x ULN w/o liver metastases or \<5 x ULN w/liver metastases
* Renal: Creatinine \< 2.0 mg/dL
* Cardiovascular: Patients with LVEF \>/= 50% by MUGA or 2D-ECHO.
* Pulmonary: Patients with DFCO and FEV1 \>/= 60% by required Pulmonary Function Tests.
* Other: Patients agreeing to use a medically effective method of contraception while enrolled in the study. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
References: